No Data
No Data
New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
DBS Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Cuts Target Price to $285
Express News | QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples
Stocks That Are Set to Benefit From Either Harris or Trump Winning Scenarios – Barclays
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Announces Target Price $265
Becton, Dickinson Launches Syringe With Thinner Wall Cannula